Celladon Corp (CLDN) 11.63 $CLDN
Celladon Selected to Present During the "Best of Circulation Research" Symposium at the American Heart Association Scientific Sessions 2014
GlobeNewswire - Fri Nov 14, 7:00AM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that Krisztina Zsebo, Ph.D., Chief Executive Officer of Celladon, was selected to present three-year long-term follow up data of MYDICAR in patients with advanced heart failure during the "Best of Circulation Research" Symposium at the American Heart Association (AHA) Scientific Sessions 2014 on Sunday, November 16, 2014 in Chicago.
CLDN: 11.63 (-0.56)
Celladon Net loss of $8.35M
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 6:18AM CST
CLDN: 11.63 (-0.56)
Celladon Reports Third Quarter 2014 Financial Results and Recent Highlights
GlobeNewswire - Wed Nov 12, 5:00AM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced financial results for the quarter ended September 30, 2014 and recent corporate highlights and updates.
CLDN: 11.63 (-0.56)
Celladon Corporation to Present at Credit Suisse Healthcare Conference
GlobeNewswire - Fri Nov 07, 3:05PM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that Krisztina Zsebo, Ph.D., Chief Executive Officer, will present a corporate overview at the Credit Suisse Healthcare Conference, being held at the Arizona Biltmore Hotel, Scottsdale, Arizona.
CLDN: 11.63 (-0.56)
Celladon Corporation to Present at Credit Suisse Healthcare Investor Conference
GlobeNewswire - Wed Nov 05, 3:38PM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that Krisztina Zsebo, Ph.D., Chief Executive Officer, will present a corporate overview at the Credit Suisse Healthcare Conference, being held at the Arizona Biltmore Hotel, Scottsdale, Arizona.
CLDN: 11.63 (-0.56)
Lonza and Celladon Corporation Establish a Strategic Commercial Manufacturing Collaboration for MYDICAR(R)
GlobeNewswire - Mon Nov 03, 5:00AM CST
-- Agreement enhances existing relationship between Celladon and Lonza for the manufacture of MYDICAR(R)
CLDN: 11.63 (-0.56)
Larsen MacColl Partners, LP Divests A&S Services Group, LLC
Business Wire - Fri Oct 31, 6:00AM CDT
Larsen MacColl Partners, LP ("LMP"
, announced today that on October 24, 2014 it sold its portfolio company, A&S Services Group, LLC and affiliates (collectively, "A&S" , to Celadon Group, Inc. The purchase price was $55 million and LMP will realize a 24x multiple of its invested capital from the sale.
CLDN: 11.63 (-0.56)
Celadon Group Reports September Quarter Results and Declares Dividend
PR Newswire - Wed Oct 29, 4:20PM CDT
Celadon Group Inc. (NYSE : CGI) today reported its financial and operating results for the three months ended September 30, 2014, the first quarter of the Company's fiscal year ending June 30, 2015.
CLDN: 11.63 (-0.56), CGI: 21.73 (-0.07)
Celadon Group Acquires A&S Services Group, LLC
PR Newswire - Mon Oct 27, 1:27PM CDT
Celadon Group, Inc. (NYSE: CGI) "Celadon", one of North America's premier transportation and logistics companies, today announced the acquisition of A&S Services Group, LLC ("A&S" . A&S is a leading regional for-hire and dedicated truckload carrier based in New Freedom, PA. A&S's fleet operations provide dry van transportation services almost exclusively and principally serve the Mid-Atlantic and Northeast regions. A&S is also a major supplier of logistics, warehousing and distribution services in the area.
CLDN: 11.63 (-0.56), CGI: 21.73 (-0.07)
Celladon Corporation Announces Publication of Data From Its Stem Cell Factor Gene Therapy Program in Circulation Heart Failure
GlobeNewswire - Mon Oct 27, 6:00AM CDT
Celladon Corporation (Nasdaq:CLDN), a biotechnology industry leader in the field of cardiovascular gene therapy, today announced together with researchers at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, the results of pre-clinical work on the membrane-bound form of the Stem Cell Factor (mSCF) gene therapy product candidate in the September 2014 online issue of Circulation Heart Failure. The paper is entitled "Stem Cell Factor Gene Therapy Improves Cardiac Function after Myocardial Infarction in Swine".
CLDN: 11.63 (-0.56)
Celadon Group Announces Executive Team Changes
PR Newswire - Tue Oct 21, 3:57PM CDT
Celadon Group, Inc. (NYSE: CGI) today announced changes to its executive team. The changes are effective immediately.
CLDN: 11.63 (-0.56), CGI: 21.73 (-0.07)
Celadon Group Announces Dates for Earnings Release and Conference Call and for Upcoming Investor Conferences
PR Newswire - Fri Oct 03, 9:19AM CDT
Celadon Group Inc. (NYSE: CGI) will release its fiscal 2015 first quarter results on Wednesday, October 29 after the close of the market. A conference call to discuss the first quarter results will be held Thursday, October 30 at 11:00 a.m. Eastern Time.
CLDN: 11.63 (-0.56), CGI: 21.73 (-0.07)
Micro-Cap Biotechs: The Next Billion Dollar Drug Is Coming From...?
OptionVol - Thu Oct 02, 5:33PM CDT
This visualization is provided by: Capital Market Laboratories (join the queue: free trial) Micro Cap Bio-techs: Who's Investing in R&D? Note that the firms above the blue line I've drawn in are pouring in at least $0.60 into researc...
LOXO: 11.45 (-0.06), DNDN: 0.11 (-0.02), VNDA: 11.81 (-0.36), OSIR: 13.05 (-0.25), CLDN: 11.63 (-0.56), GALE: 1.87 (-0.01), CTIC: 2.13 (-0.02), OTIC: 23.36 (-0.33)
Celladon to Present at the 2014 Stem Cell Meeting on the Mesa
GlobeNewswire - Wed Oct 01, 3:15PM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that Krisztina Zsebo, Ph.D., Chief Executive Officer, will present a corporate overview at the 4th Annual Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, CA.
CLDN: 11.63 (-0.56)
Celladon Corporation Appoints Scott Garrett Vice President, Commercial Planning
GlobeNewswire - Mon Sep 22, 7:07AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced it has appointed Scott Garrett as Vice President, Commercial Planning, a newly created position.
JNJ: 108.16 (-0.91), GILD: 102.06 (-2.14), CLDN: 11.63 (-0.56)
Global Chronic Heart Failure Therapeutics Pipeline Review 2014 - 21 Companies & 31 Drug Profiles
M2 - Thu Sep 11, 4:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wx7flm/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Amgen Inc. - Sanofi - Novartis AG - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Pfizer Inc. - Bayer AG - Celladon Corporation - Mesoblast Limited - Palatin Technologies, Inc. - AnGes MG, Inc. - MetrioPharm AG - Cyano Biotech GmbH - NormOxys, Inc. - Cardioxyl Pharmaceuticals, Inc. - PhaseBio Pharmaceuticals, Inc. - miRagen Therapeutics, Inc. - Fibrotech Therapeutics Pty. Ltd. - Otsuka Holdings Co., Ltd. - Zensun (Shanghai) Sci & Tech Co., Ltd. Drug Profiles - Neucardin - rivaroxaban - (sacubitril valsartan) - CEP-41750 - aliskiren fumarate - sildenafil citrate - ivabradine - PL-3994 - omecamtiv mecarbil - Mydicar - CXL-1020 - serelaxin (recombinant) - tolvaptan - finerenone - ivabradine - F-373280 - Stem Cell Therapy for Cardiovascular Diseases - cenderitide - beperminogene perplasmid - OXY-111A - Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure - MGN-9103 - BR-5489 - FT-011 - PB-1046 - Cell Therapy for Chronic Heart Failure - SAR-296968 - RNAi Gene Therapy to Inhibit STIM1 for Cardiovascular Diseases - Peptides Inhibiting ACE for Cardiovascular and Metabolic Disorders - Vestiras For more information visit http://www.researchandmarkets.com/research/wx...onic_heart
PFE: 30.34 (-0.08), PTN: 0.75 (unch), CLDN: 11.63 (-0.56), AMGN: 157.68 (-3.17), NVS: 93.95 (-0.43)
Nasdaq stocks posting largest percentage increases
AP - Fri Sep 05, 2:45PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
LOXO: 11.45 (-0.06), ACET: 21.10 (-0.19), MAGS: 4.51 (-0.06), CLDN: 11.63 (-0.56)
Why You Shouldn't Bet Against Celladon Corporation (CLDN) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 7:57AM CDT
Celladon is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
CLDN: 11.63 (-0.56)
Celladon Corp. (CLDN) Jumps: Stock Adds 11.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 7:51AM CDT
Celladon Corporation (CLDN) was a big mover last session, as its shares rose over 11% on the day.
CBPO: 66.60 (+0.25), CBM: 23.17 (-0.19), GILD: 102.06 (-2.14), CLDN: 11.63 (-0.56)
Celladon Selected to Present During the "Best of Circulation Research" Symposium at the American Heart Association Scientific Sessions 2014
GlobeNewswire - Fri Nov 14, 7:00AM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that Krisztina Zsebo, Ph.D., Chief Executive Officer of Celladon, was selected to present three-year long-term follow up data of MYDICAR in patients with advanced heart failure during the "Best of Circulation Research" Symposium at the American Heart Association (AHA) Scientific Sessions 2014 on Sunday, November 16, 2014 in Chicago.
CLDN: 11.63 (-0.56)
Celladon Net loss of $8.35M
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 6:18AM CST
CLDN: 11.63 (-0.56)
Celladon Reports Third Quarter 2014 Financial Results and Recent Highlights
GlobeNewswire - Wed Nov 12, 5:00AM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced financial results for the quarter ended September 30, 2014 and recent corporate highlights and updates.
CLDN: 11.63 (-0.56)
Celladon Corporation to Present at Credit Suisse Healthcare Conference
GlobeNewswire - Fri Nov 07, 3:05PM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that Krisztina Zsebo, Ph.D., Chief Executive Officer, will present a corporate overview at the Credit Suisse Healthcare Conference, being held at the Arizona Biltmore Hotel, Scottsdale, Arizona.
CLDN: 11.63 (-0.56)
Celladon Corporation to Present at Credit Suisse Healthcare Investor Conference
GlobeNewswire - Wed Nov 05, 3:38PM CST
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that Krisztina Zsebo, Ph.D., Chief Executive Officer, will present a corporate overview at the Credit Suisse Healthcare Conference, being held at the Arizona Biltmore Hotel, Scottsdale, Arizona.
CLDN: 11.63 (-0.56)
Lonza and Celladon Corporation Establish a Strategic Commercial Manufacturing Collaboration for MYDICAR(R)
GlobeNewswire - Mon Nov 03, 5:00AM CST
-- Agreement enhances existing relationship between Celladon and Lonza for the manufacture of MYDICAR(R)
CLDN: 11.63 (-0.56)
Larsen MacColl Partners, LP Divests A&S Services Group, LLC
Business Wire - Fri Oct 31, 6:00AM CDT
Larsen MacColl Partners, LP ("LMP"
, announced today that on October 24, 2014 it sold its portfolio company, A&S Services Group, LLC and affiliates (collectively, "A&S" , to Celadon Group, Inc. The purchase price was $55 million and LMP will realize a 24x multiple of its invested capital from the sale. CLDN: 11.63 (-0.56)
Celadon Group Reports September Quarter Results and Declares Dividend
PR Newswire - Wed Oct 29, 4:20PM CDT
Celadon Group Inc. (NYSE : CGI) today reported its financial and operating results for the three months ended September 30, 2014, the first quarter of the Company's fiscal year ending June 30, 2015.
CLDN: 11.63 (-0.56), CGI: 21.73 (-0.07)
Celadon Group Acquires A&S Services Group, LLC
PR Newswire - Mon Oct 27, 1:27PM CDT
Celadon Group, Inc. (NYSE: CGI) "Celadon", one of North America's premier transportation and logistics companies, today announced the acquisition of A&S Services Group, LLC ("A&S"
. A&S is a leading regional for-hire and dedicated truckload carrier based in New Freedom, PA. A&S's fleet operations provide dry van transportation services almost exclusively and principally serve the Mid-Atlantic and Northeast regions. A&S is also a major supplier of logistics, warehousing and distribution services in the area. CLDN: 11.63 (-0.56), CGI: 21.73 (-0.07)
Celladon Corporation Announces Publication of Data From Its Stem Cell Factor Gene Therapy Program in Circulation Heart Failure
GlobeNewswire - Mon Oct 27, 6:00AM CDT
Celladon Corporation (Nasdaq:CLDN), a biotechnology industry leader in the field of cardiovascular gene therapy, today announced together with researchers at the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai, the results of pre-clinical work on the membrane-bound form of the Stem Cell Factor (mSCF) gene therapy product candidate in the September 2014 online issue of Circulation Heart Failure. The paper is entitled "Stem Cell Factor Gene Therapy Improves Cardiac Function after Myocardial Infarction in Swine".
CLDN: 11.63 (-0.56)
Celadon Group Announces Executive Team Changes
PR Newswire - Tue Oct 21, 3:57PM CDT
Celadon Group, Inc. (NYSE: CGI) today announced changes to its executive team. The changes are effective immediately.
CLDN: 11.63 (-0.56), CGI: 21.73 (-0.07)
Celadon Group Announces Dates for Earnings Release and Conference Call and for Upcoming Investor Conferences
PR Newswire - Fri Oct 03, 9:19AM CDT
Celadon Group Inc. (NYSE: CGI) will release its fiscal 2015 first quarter results on Wednesday, October 29 after the close of the market. A conference call to discuss the first quarter results will be held Thursday, October 30 at 11:00 a.m. Eastern Time.
CLDN: 11.63 (-0.56), CGI: 21.73 (-0.07)
Micro-Cap Biotechs: The Next Billion Dollar Drug Is Coming From...?
OptionVol - Thu Oct 02, 5:33PM CDT
This visualization is provided by: Capital Market Laboratories (join the queue: free trial) Micro Cap Bio-techs: Who's Investing in R&D? Note that the firms above the blue line I've drawn in are pouring in at least $0.60 into researc...
LOXO: 11.45 (-0.06), DNDN: 0.11 (-0.02), VNDA: 11.81 (-0.36), OSIR: 13.05 (-0.25), CLDN: 11.63 (-0.56), GALE: 1.87 (-0.01), CTIC: 2.13 (-0.02), OTIC: 23.36 (-0.33)
Celladon to Present at the 2014 Stem Cell Meeting on the Mesa
GlobeNewswire - Wed Oct 01, 3:15PM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced that Krisztina Zsebo, Ph.D., Chief Executive Officer, will present a corporate overview at the 4th Annual Partnering Forum, part of the Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, CA.
CLDN: 11.63 (-0.56)
Celladon Corporation Appoints Scott Garrett Vice President, Commercial Planning
GlobeNewswire - Mon Sep 22, 7:07AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company applying its leadership position in the field of gene therapy and calcium dysregulation, today announced it has appointed Scott Garrett as Vice President, Commercial Planning, a newly created position.
JNJ: 108.16 (-0.91), GILD: 102.06 (-2.14), CLDN: 11.63 (-0.56)
Global Chronic Heart Failure Therapeutics Pipeline Review 2014 - 21 Companies & 31 Drug Profiles
M2 - Thu Sep 11, 4:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wx7flm/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Hospira, Inc. - Amgen Inc. - Sanofi - Novartis AG - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Pfizer Inc. - Bayer AG - Celladon Corporation - Mesoblast Limited - Palatin Technologies, Inc. - AnGes MG, Inc. - MetrioPharm AG - Cyano Biotech GmbH - NormOxys, Inc. - Cardioxyl Pharmaceuticals, Inc. - PhaseBio Pharmaceuticals, Inc. - miRagen Therapeutics, Inc. - Fibrotech Therapeutics Pty. Ltd. - Otsuka Holdings Co., Ltd. - Zensun (Shanghai) Sci & Tech Co., Ltd. Drug Profiles - Neucardin - rivaroxaban - (sacubitril valsartan) - CEP-41750 - aliskiren fumarate - sildenafil citrate - ivabradine - PL-3994 - omecamtiv mecarbil - Mydicar - CXL-1020 - serelaxin (recombinant) - tolvaptan - finerenone - ivabradine - F-373280 - Stem Cell Therapy for Cardiovascular Diseases - cenderitide - beperminogene perplasmid - OXY-111A - Small Molecule to Inhibit Beta-1 Adrenergic Receptor for Chronic Heart Failure - MGN-9103 - BR-5489 - FT-011 - PB-1046 - Cell Therapy for Chronic Heart Failure - SAR-296968 - RNAi Gene Therapy to Inhibit STIM1 for Cardiovascular Diseases - Peptides Inhibiting ACE for Cardiovascular and Metabolic Disorders - Vestiras For more information visit http://www.researchandmarkets.com/research/wx...onic_heart
PFE: 30.34 (-0.08), PTN: 0.75 (unch), CLDN: 11.63 (-0.56), AMGN: 157.68 (-3.17), NVS: 93.95 (-0.43)
Nasdaq stocks posting largest percentage increases
AP - Fri Sep 05, 2:45PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
LOXO: 11.45 (-0.06), ACET: 21.10 (-0.19), MAGS: 4.51 (-0.06), CLDN: 11.63 (-0.56)
Why You Shouldn't Bet Against Celladon Corporation (CLDN) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 7:57AM CDT
Celladon is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
CLDN: 11.63 (-0.56)
Celladon Corp. (CLDN) Jumps: Stock Adds 11.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 7:51AM CDT
Celladon Corporation (CLDN) was a big mover last session, as its shares rose over 11% on the day.
CBPO: 66.60 (+0.25), CBM: 23.17 (-0.19), GILD: 102.06 (-2.14), CLDN: 11.63 (-0.56)
